Popular Articles

Yale Launches Global Health Initiative
In an ambitious effort to further Yale University"s engagement in global health, President Richard C. Levin announced today the launch of the Yale Global Health Initiative. This is the first endeavor of the University"s new Jackson Institute of Global Affairs, which was announced in April. The purpose of the new initiative is to unite the many global health efforts across campus, foster innovative educational programs to address the growing student interest in global health, and stimulate and support faculty research to enhance healthcare around the world. Buy arimidex to treat cancer.

PLC Medical Systems To Demonstrate RenalGuard(R) At EuroPCR 2009
PLC Systems Inc. (OTC Bulletin Board: PLCSF), a company focused on innovative cardiac and vascular medical device-based technologies, announced that it will demonstrate its RenalGuard System(TM) at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), May 19-22, 2009, in Barcelona, Spain. More than 11,000 clinicians and professionals are expected to attend this event.

generic viagra online


News of the day
Health Subcommittee Considers Bill To Eliminate Pre-Emption For Medical Devices
The House Energy and Commerce Health Subcommittee on Tuesday heard testimony on the Medical Device Safety Act of 2009 (HR 1346), which would allow consumers to sue medical device manufacturers in state courts, CQ HealthBeat reports. The bill responds to last year"s Supreme Court ruling that says medical devices with FDA pre-marketing approval can be pre-empted from lawsuits under state law, in accordance with the Medical Device Amendments of 1976. Rep. Frank Pallone (D-N.Y.), who introduced the bill, said that the 2008 Supreme Court ruling "ignor[ed] congressional intent" by providing blanket immunity for medical device makers. According to Rep. John Dingell (D-Mich.), a co-sponsor of the bill, the original 1976 law sought to grant regulatory authority to FDA for medical devices, but it did not aim to eliminate state liability. Committee Chair Rep. Henry Waxman (D-Calif.), another co-sponsor, said last year"s ruling already has caused 1,400 injury cases to be thrown out of court, adding that the threat of litigation provides manufacturers with additional safety incentives. David Vladeck -- a law professor at Georgetown University Law Center who testified at the hearing -- added that immunity from lawsuits "removes incentive to manufacturers to fix devices quickly and get defective devices off the market."Rep. Nathan Deal (R-Ga.) said the class of device that must obtain pre-marketing approval -- which includes pacemakers and replacement heart valves -- represents only 2% of all approved medical devices each year. Rep. Michael Burgess (R-Texas) added that the measure could create an inconsistent system that allows both FDA experts and jurors in various states to make decisions on medical device safety standards. In addition, Rep. Joe Pitts (R-Pa.) cautioned that the bill might encourage manufacturers to limit distribution of their devices to certain states (Kim, CQ HealthBeat, 5/13). Related Editorial
Cardiovascular

Stanford Study Recruiting Participants Who Have Insomnia And Depression

"You"ll feel better after a good night"s sleep." We"ve all heard those words, but have we ever stopped to wonder about the mental health of people who just aren"t able to sleep well? Rachel Manber has, and the Stanford University School of Medicine researcher is trying to identify the best way to treat patients suffering from both depression and insomnia. Manber, PhD, an associate professor of psychiatry and behavioral sciences, is seeking volunteers for a first-of-its-kind study on the benefits of combining the treatments of medication for depression and psychotherapy for sleep difficulties. Depression and insomnia, defined as having difficulty initiating and/or maintaining sleep, are very much linked. "Insomnia is certainly a risk factor for depression: studies show that having insomnia increases a person"s risk of developing depression in one to three years," Manber said. At the same time, Manber pointed out, depressed patients with sleep problems don"t respond as well to standard depression treatments as other patients. This is a problem because between 60 and 84 percent of patients with major depression also sleep poorly. In addition, if a sleep disorder goes untreated, a patient is at a greater risk for a future relapse of depression. The multicenter study, which will involve 255 people, aims to determine whether combining antidepressant medications and insomnia therapy will improve the lives of people who experience both conditions simultaneously. Manber plans to enroll 85 patients at Stanford; participants must be between the ages of 18 and 75, suffering from insomnia and depression, and not currently receiving treatment for either disorder. During the study, participants will receive free evaluations of their sleep, including an at-home, all-night sleep study. Participants will also receive 16 weeks of one of three FDA-approved antidepressant medications (Lexapro, Zoloft or Pristique) and will be randomized into receiving seven sessions of one of two forms of sleep-focused psychotherapies for insomnia. Interested men and women should contact Rachel Wells at (650) 723-2641 for a free telephone screening. The study is funded by the National Institute of Mental Health and led by the Stanford site. Other centers participating in the study are Duke University and the University of Pittsburgh. The Stanford University School of Medicine


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):